Recent 8-K filings for TLRY
Highest-materiality recent filing
Tilray acquires UK medical platform Lyphe; files $180M ATM for beverage expansion
- Acquired Lyphe Group, a UK medical cannabis clinic/pharmacy; dispensed ~150K units, treated 16K+ patients; expected accretive in 2027.
- Filed ATM equity program of up to $180M to invest in global beverage platform; managed by Jefferies, TD Securities, Roth Capital.
-
Tilray acquires UK medical platform Lyphe; files $180M ATM for beverage expansion
Acquired Lyphe Group, a UK medical cannabis clinic/pharmacy; dispensed ~150K units, treated 16K+ patients; expected accretive in 2027.
-
Tilray Brands Q3 FY2026 revenue $207M record; intl cannabis +73%; buys BrewDog ~£40M
Record Q3 net revenue of $207M, up 11% organic YoY; gross profit $55M, up 6% YoY.
-
Tilray Brands acquires BrewDog assets for £33M; eyes $200M annual revenue from acquisition
Acquired BrewDog's global IP, UK brewing ops, and 11 brewpubs for £33M (~$44.1M) via pre-pack administration.
-
Tilray Brands Q2 FY2026 revenue record $218M; net cash $30M; reaffirms EBITDA guidance
Net revenue $218M, a record quarterly; international medical cannabis revenue increased 36% YoY.
-
Tilray Brands Q1 FY2026 net revenue $210M, net income $1.5M, EBITDA +9%
Net revenue $209.5M (+5% YoY); net income $1.5M vs net loss $34.7M prior year.
-
Tilray Q4/FY2025: net loss $1.27B on $2.1B impairment; guides FY2026 EBITDA $62-72M
FY2025 net revenue $821.3M (+4% YoY); Q4 net revenue $224.5M (down 2% from $229.9M).
-
Tilray shareholders approve reverse stock split up to 1-for-20
Shareholders approved amendment to allow reverse stock split at ratio between 1:10 and 1:20; 251M for, 182M against.
-
Tilray exchanges $9.4M convertible notes for 19M shares in private deals
Issued 19,034,603 common shares in exchange for $9.4M aggregate principal of 5.20% Convertible Senior Notes due June 2027.
-
Tilray Q3 net revenue $186M; adjusted EBITDA $9M; cannabis margin up 800bps; debt reduced $71M
Net revenue $185.8M vs $188.3M prior year; constant currency ~$193M; SKU rationalization hit $13.2M.
-
Tilray Brands gets 180 days to cure Nasdaq minimum bid price deficiency
Received Nasdaq notice on March 25, 2025 for non-compliance with $1.00 minimum bid price rule.
-
Tilray to issue up to 23M shares in exchange for $14.6M convertible notes
Up to 23M shares issued in private exchange for $14.6M principal of 5.20% Convertible Notes due June 2027.
-
Tilray subsidiary refinances CAD $53M term loan to CIBC; extends maturity to 2028
Aphria Diamond Inc. entered a CAD $53M credit agreement with CIBC on Feb 21, 2025.
-
Tilray subsidiary Aphria settles Canadian class action for CAD 30M; no admission of liability
Settled for CAD 30M (US 21M), far below original CAD 875M claim; dismissal with prejudice.
-
Tilray Brands Q2 revenue up 9% to $211M; gross profit +29%; reaffirms FY2025 guidance
Net revenue $211M (record Q2), +9% YoY; gross margin 29% vs 24% prior year.
-
Delaware court grants summary judgment for Tilray in proxy vote lawsuit
Court held Tilray correctly used majority-of-votes-cast standard for authorized share proposals; granted summary judgment for Tilray and directors.
-
Tilray faces shareholder class action challenging authorized share vote standard
Lawsuit filed Oct 31, 2024 in Delaware Chancery claims proxy statements improperly used votes-cast standard instead of majority-of-outstanding shares for share increases.
-
Tilray Q1 revenue $200M (+13%), net loss narrows; beverage alcohol up 132%
Net revenue $200M (+13% YoY); gross margin 30% (+500 bps) to $59.7M.
-
Tilray FY2024 revenue up 26% to $789M, debt cut $291M, adjusted EBITDA $60.5M
Net revenue $788.9M (+26% YoY); Q4 revenue $229.9M (+25%).
-
May offer and sell up to $250M of common stock through TD Securities and Jefferies in at-the-market offerings.
-
Tilray converts $19.8M of 2024 convertible notes to 13.1M shares; only $330K notes remaining
Expects to issue up to 13.1M shares of common stock in exchange for $19.8M aggregate principal of 5.25% Convertible Senior Notes due June 1, 2024.
-
Tilray to issue up to 15.2M shares in exchange for $24M of convertible notes
Between April 24 and May 6, 2024, Tilray entered private debt-for-equity exchanges with unrelated parties.
-
Tilray Q3 revenue up 30% to $188M; adjusts FY EBITDA guidance to $60-63M
Net revenue $188.3M (+30% YoY); beverage-alcohol revenue surged 165% to $54.7M on craft acquisitions.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material